We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Analysis of Lymphocyte Cell Surface Adhesion Marker Expression in Natalizumab Population With Active Control

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01626248
First Posted: June 22, 2012
Last Update Posted: June 14, 2013
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborators:
Biogen
Elan Pharmaceuticals
Information provided by (Responsible Party):
John F. Foley, MD, Rocky Mountain MS Research Group, LLC
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: April 2013
  Primary Completion Date: March 2013 (Final data collection date for primary outcome measure)